HONASAHonasa Consumer Ltd.

    Honasa Consumer Q2 FY27 Results: Consolidated Net Profit ₹73.25 Crore on Total Income of ₹753 Crore

    • Earnings
    • Beauty and personal care

    Honasa Consumer (NSE: HONASA) reported consolidated total income of ₹752.94 crore and net profit of ₹73.25 crore for the quarter ended 30 Sep 2026, it said in a filing on 06 Nov 2026. Standalone total income was ₹710.51 crore and standalone net profit ₹71.70 crore.

    Key highlights

    Consolidated

    Including its subsidiaries

    • Total income: ₹752.94 crore, up 34.9% YoY and 3.3% QoQ
    • Net profit and EPS: ₹73.25 crore, up 86.7% YoY; basic EPS ₹2.24 against ₹1.21
    • Finance costs: ₹3.17 crore, down 3.9% YoY and up 4.8% QoQ

    Standalone

    The company on its own, without its subsidiaries

    • Total income: ₹710.51 crore, up 30.0% YoY and down 1.1% QoQ
    • Net profit and EPS: ₹71.70 crore, up 87.0% YoY; basic EPS ₹2.20 against ₹1.18
    • Finance costs: ₹2.53 crore, down 6.8% YoY and up 4.5% QoQ

    Summary

    Consolidated ₹ crore
    ParticularsQ2 FY27Q2 FY26YoYQ1 FY27QoQ
    752.94558.20+34.9%778.46-3.3%
    73.2539.23+86.7%90.45-19.0%
    EPS, basic (₹)2.241.21+85.1%2.77-19.1%

    Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.

    Net profit grew faster than total income this quarter: profit rose 86.7% year on year against 34.9% for total income. Profit before tax rose 91.1%, and tax expense rose 103.8% to ₹27.55 crore, so the net profit margin widened from 7.03% to 9.73%.

    Other income of ₹21.76 crore is 2.9% of total income and 21.6% of profit before tax of ₹100.80 crore. Revenue from operations of ₹731.19 crore grew 35.9% year on year, faster than other income, which rose 8.0%.

    Against the previous quarter, net profit fell 19.0% while total income fell 3.3%. The filing shows no exceptional item in the quarter; its only exceptional item is ₹4.80 crore, a past service cost from the Labour Codes, in the year ended 31 Mar 2026.

    Other expenses and purchases of traded goods rose in the quarter, and the filing does not give the reason for the rise. The notes say the company has evaluated the Labour Codes and will keep monitoring them.

    Standalone ₹ crore
    ParticularsQ2 FY27Q2 FY26YoYQ1 FY27QoQ
    710.51546.64+30.0%718.24-1.1%
    71.7038.35+87.0%84.31-15.0%
    EPS, basic (₹)2.201.18+86.4%2.59-15.1%

    Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.

    Standalone net profit rose 87.0% year on year, against 30.0% growth in total income. Profit before tax rose 89.7% to ₹97.64 crore, and the net profit margin widened from 7.02% to 10.09%.

    Consolidated net profit of ₹73.25 crore is ₹1.55 crore higher than standalone net profit of ₹71.70 crore. Consolidated total income of ₹752.94 crore is ₹42.43 crore higher than standalone total income of ₹710.51 crore.

    Standalone other income of ₹21.12 crore is 3.0% of total income and 21.6% of profit before tax. Depreciation fell 10.8% year on year to ₹8.29 crore, while finance costs of ₹2.53 crore are 0.4% of total income.

    The company is a trader of beauty and personal care products, which it says are manufactured through third-party contract manufacturers, and it operates as one segment. The Board approved the results on 06 Nov 2026, and the results were reviewed by the statutory auditors, S.R. Batliboi & Associates LLP, who issued unmodified limited review conclusions.

    The Board recommended a final dividend of ₹3 per share for FY2025-26, approved by shareholders at the 10th Annual General Meeting on 28 Sep 2026. The dividend aggregating ₹97.81 crore has been recognised in the quarter and half year. The company also says that it has allotted 654,422 equity shares on exercise of stock options, raising paid-up capital to ₹3,260.24 million.

    Inference

    The filing says the Board approved an acquisition of a 58% equity stake in Fluence Pharma Private Limited on 23 Jun 2026 and called it off on 25 Aug 2026 because closing conditions were not fulfilled. The amount of consideration and any other reason for calling it off are not stated.

    The company says it is seeking legal advice on enforcing an arbitral award of AED 9.92 million (₹25.54 crore) against RSM General Trading LLC, and that it does not expect any material financial impact as on date. The timing or outcome of enforcement is not stated.

    The Honasa Health subsidiary was incorporated on 7 Jul 2026 with capital of ₹1 lakh, and a scheme to amalgamate B:Blunt Spratt into BBlunt is subject to statutory approvals. The filing does not say how these will be funded or when they will complete.

    Filed with BSE on . Reference: Original filing (PDF)

    Disclaimer:

    The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

    Latest posts